Abstract

Within a single-institution phase II trial, we investigated the antitumor activity of the Raltitrexed–Oxaliplatin combination as second-line therapy for malignant pleural mesothelioma (MPM). Fourteen patients were enrolled and all were assessable for response. The trial was then closed because chemotherapy, though well tolerated, yielded no objective responses. The best response observed was disease stabilization in 4 patients only (28.57%), while the other 10 patients (71.42%) progressed despite treatment. Median time to progression (TTP) was 8 weeks (average: 9.85, range: 7–20), while median overall survival was just 14 weeks (average: 21.69, range: 9–66+).